{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T08:23:27Z","timestamp":1779179007364,"version":"3.51.4"},"reference-count":29,"publisher":"Oncology Nursing Society (ONS)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CJON"],"published-print":{"date-parts":[[2015,6,1]]},"DOI":"10.1188\/15.cjon.e47-e51","type":"journal-article","created":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T13:07:22Z","timestamp":1441112842000},"page":"E47-E51","source":"Crossref","is-referenced-by-count":3,"title":["Ibrutinib: A New Targeted Therapy for Hematologic Cancers"],"prefix":"10.1188","volume":"19","author":[{"given":"Caroline","family":"Smithson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1302","published-online":{"date-parts":[[2015,6,1]]},"reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"Advani, R.H., Buggy, J.J., Sharman, J.P., Smith, S.M., Boyd, T.E., Grant, B., . . . Fowler, N.H. (2013). Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies. Journal of Clinical Oncology, 31, 88\u201394. doi:10.1200.JCO.2012.42.7906","DOI":"10.1200\/JCO.2012.42.7906"},{"key":"2","unstructured":"Berkrot, B. (2013, December 8). Leukemia drug ibrutinib effective in long-term study. Retrieved from http:\/\/www.huffingtonpost .com\/2013\/12\/09\/leukemia-drug-ibrutinib_n_4408276.html"},{"key":"3","doi-asserted-by":"crossref","unstructured":"Bhatt, V., Alejandro, L., Michael, A., & Ganetsky, A. (2014). The promising impact of ibrutinib, a Bruton\u2019s tyrosine kinase inhibitor, for the management of lymphoid malignancies. Pharmacotherapy, 34, 303\u2013314. doi:10.1002\/phar.1366","DOI":"10.1002\/phar.1366"},{"key":"4","unstructured":"Byrd, J.C., Brown, J.R., O\u2019Brien, S., Barrientos, J.C., Kay, N.E., Reddy, N.M., . . . Hillmen, P. (2014). Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. New England Journal of Medicine, 371, 213\u2013223. doi:10.1056\/NEJMoa 1400376"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Cameron, F., & Sanford, M. (2014). Ibrutinib: First global approval. Drugs, 74, 263\u2013271. doi:10.1007\/s40265-014-0178-8","DOI":"10.1007\/s40265-014-0178-8"},{"key":"6","doi-asserted-by":"crossref","unstructured":"Chavez, J.C., Sahakian, E., & Pinilla-Ibarz, J. (2013). Ibrutinib: An evidence-based review of its potential in the treatment of advanced chronic lymphocytic leukemia. Core Evidence, 8, 37\u201345. doi:10.2147\/CE.S34068","DOI":"10.2147\/CE.S34068"},{"key":"7","unstructured":"Chustecka, Z. (2014, January 9). CLL trial stopped as ibrutinib shows significant benefits. Retrieved from http:\/\/www.medscape .com\/viewarticle\/818948"},{"key":"8","unstructured":"European Organisation for the Research and Treatment of Cancer. Quality of Life Group. (1995). EORTC QLQ-C30 (version 3). Retrieved from http:\/\/groups.eortc.be\/qol\/sites\/default\/files\/img\/slider\/specimen_qlq-c30_english.pdf"},{"key":"9","unstructured":"Greener, M. (2009). Understanding the principles of drug metabolism. Nurse Prescribing, 7, 109\u2013114. doi:10.12968\/npre.2009.7.3 .40690"},{"key":"10","unstructured":"Manson, S.D., & Porter, C. (2011). Lymphomas. In C.H. Yarbro, D. Wujcik, & B.H. Gobel (Eds.), Cancer nursing: Principles and practice (pp. 1458\u20131512). Sudbury, MA: Jones and Bartlett."},{"key":"11","unstructured":"National Cancer Institute. (2015). Clinical trials search results. Retrieved from http:\/\/www.cancer.gov\/clinicaltrials\/search\/ results?protocolsearchid=6909086"},{"key":"12","unstructured":"National Comprehensive Cancer Network. (2015). NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin\u2019s lymphomas [v.2.2015]. Retrieved from http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nhl.pdf"},{"key":"13","unstructured":"Neuss, M.N., Polovich, M., McNiff, K., Esper, P., Gilmore, T.R., LeFebvre, K.B., . . . Jacobson, J.O. (2013). 2013 updated American Society of Clinical Oncology\/Oncology Nursing Society chemotherapy administration safety standards including standards for the safe administration and management of oral chemotherapy. Oncology Nursing Forum, 40, 225\u2013233. doi:10.1188\/13.ONF.40 -03AP2"},{"key":"14","unstructured":"O\u2019Brien, S., Furman, R.R., Coutre, S.E., Sharman, J.P., Burger, J.A., Blum, K.A., . . . Byrd, J.C. (2014). Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: An open-label, multicentre, phase 1b\/2 trial. Lancet Oncology, 15, 48\u201358. doi:10.1016\/S1470-2045 (13)70513-8"},{"key":"15","unstructured":"Pharmacyclics, Inc. (2015). Imbruvica\u00ae (ibrutinib) capsules, for oral use: Highlights of prescribing information. Retrieved from https:\/\/www.imbruvica.com\/downloads\/Prescribing_Inform ation.pdf"},{"key":"16","unstructured":"Pollack, A. (2013, November 13). Imbruvica, drug approved to treat blood cancer, gains F.D.A. approval. Retrieved from http:\/\/www .nytimes.com\/2013\/11\/14\/business\/drug-to-treat-blood-cancer -gains-fda-approval.html"},{"key":"17","unstructured":"RxList Inc. (2015). Imbruvica. Retrieved from http:\/\/www.rxlist.com\/ imbruvica-drug.htm"},{"key":"18","unstructured":"Schneider, S.M., Adams, D.B., & Gosselin, T. (2014). A tailored nurse coaching intervention for oral chemotherapy adherence. Journal of the Advanced Practitioner in Oncology, 5, 163\u2013172."},{"key":"19","doi-asserted-by":"crossref","unstructured":"Treon, S.P., Tripsas, C.K., Meid, K., Warren, D., Varma, G., Green, R., . . . Advani, R.H. (2015). Ibrutinib in previously treated Waldenstr\u00f6m\u2019s macroglobulinemia. New England Journal of Medicine, 372, 1430\u20131440. doi:10.1056\/NEJMoa1501548","DOI":"10.1056\/NEJMoa1501548"},{"key":"20","unstructured":"University of Texas MD Anderson Cancer Center. (2013, December 9). Ibrutinib and rituximab trigger 95 percent response rate among CLL patients. Retrieved from http:\/\/www.mdanderson .org\/newsroom\/news-releases\/2013\/ibrutinib-and-rituximab -trigger.html"},{"key":"21","unstructured":"U.S. Food and Drug Administration. (2013a, November 13). FDA approves Imbruvica for rare blood cancer. Retrieved from http:\/\/www.fda.gov\/newsevents\/newsroom\/pressannouncements\/ucm374761.htm"},{"key":"22","unstructured":"U.S. Food and Drug Administration. (2013b, November 13). Ibrutinib. Retrieved from http:\/\/www.fda.gov\/drugs\/informationondrugs\/ approveddrugs\/ucm374857.htm"},{"key":"23","unstructured":"U.S. Food and Drug Administration. (2014a, February 13). Ibrutinib (Imbruvica). Retrieved from http:\/\/www.fda.gov\/drugs\/information ondrugs\/approveddrugs\/ucm385878.htm"},{"key":"24","unstructured":"U.S. Food and Drug Administration. (2014b, July 28). FDA expands approved use of Imbruvica for chronic lymphocytic leukemia. Retrieved from http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm406916.htm"},{"key":"25","unstructured":"U.S. Food and Drug Administration. (2015, January 29). FDA expands use of Imbruvica for rare form of non-Hodgkin lymphoma. Retrieved from http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm432123.htm"},{"key":"26","doi-asserted-by":"crossref","unstructured":"Wang, M.L., Rule, S., Martin, P., Goy, A., Auer, R., Kahl, B.S., . . . Blum, K.A. (2013). Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. New England Journal of Medicine, 369, 507\u2013516. doi:10.1056\/NEJMoa1306220","DOI":"10.1056\/NEJMoa1306220"},{"key":"27","doi-asserted-by":"crossref","unstructured":"Wiestner, A. (2013). Targeting B-cell receptor signaling for anticancer therapy: The Bruton\u2019s tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies. Journal of Clinical Oncology, 31, 128\u2013130. doi:10.1200\/JCO.2012.44.4281","DOI":"10.1200\/JCO.2012.44.4281"},{"key":"28","unstructured":"Wilkes, G.M. (2011). Chemotherapy: Principles of administration. In C.H. Yarbro, D. Wujcik, & B.H. Gobel (Eds.), Cancer nursing: Principles and practice (pp. 390\u2013457). Sudbury, MA: Jones and Bartlett."},{"key":"29","unstructured":"Wujcik, D. (2011). Targeted therapy. In C.H. Yarbro, D. Wujcik, & B.H. Gobel (Eds.), Cancer nursing: Principles and practice (pp. 561\u2013583). Sudbury, MA: Jones and Bartlett."}],"container-title":["Clinical Journal of Oncology Nursing"],"original-title":[],"link":[{"URL":"http:\/\/cjon.ons.org\/cjon\/19\/3\/ibrutinib-new-targeted-therapy-hematologic-cancers","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:53:21Z","timestamp":1763754801000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ons.org\/publications-research\/cjon\/19\/3\/ibrutinib-new-targeted-therapy-hematologic-cancers"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,1]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,6,1]]}},"URL":"https:\/\/doi.org\/10.1188\/15.cjon.e47-e51","relation":{},"ISSN":["1092-1095","1538-067X"],"issn-type":[{"value":"1092-1095","type":"print"},{"value":"1538-067X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,1]]}}}